Various synthetic TLR3 agonists are available and some of them, including polyinosinic:polycytidylic acid (polyI:C) and its clinical grade analog polyI:polyC12U (also known as rintatolimod and AmpligenTM), have been extensively tested as immunostimulants in cancer patients (130, 131). This evidence concerns the gene TLR3 and cancer.